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Abstract
Background: The biological functions of epicardial adipose tissue (EAT) remain largely unknown. However, the proximity of
EAT to the coronary arteries suggests a role in the pathogenesis of coronary artery disease (CAD). The objectives of this
study were to identify genes differentially regulated among three adipose tissues, namely EAT, mediastinal (MAT) and
subcutaneous (SAT) and to study their possible relationships with the development of cardiovascular diseases.
Methods and Results: Samples were collected from subjects undergoing coronary artery bypass grafting surgeries. Gene
expression was evaluated in the three adipose depots of six men using the IlluminaH HumanWG-6 v3.0 expression
BeadChips. Twenty-three and 73 genes were differentially up-regulated in EAT compared to MAT and SAT, respectively.
Ninety-four genes were down-regulated in EAT compared to SAT. However, none were significantly down-regulated in EAT
compared to MAT. More specifically, the expression of the adenosine A1 receptor (ADORA1), involved in myocardial
ischemia, was significantly up-regulated in EAT. Levels of the prostaglandin D2 synthase (PTGDS) gene, recently associated
with the progression of atherosclerosis, were significantly different in the three pairwise comparisons (EAT.MAT.SAT). The
results of ADORA1 and PTGDS were confirmed by quantitative real-time PCR in 25 independent subjects.
Conclusions: Overall, the transcriptional profiles of EAT and MAT were similar compared to the SAT. Despite this similarity,
two genes involved in cardiovascular diseases, ADORA1 and PTGDS, were differentially up-regulated in EAT. These results
provide insights about the biology of EAT and its potential implication in CAD.
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Introduction
Increased visceral adipose tissue has been associated with the
development of cardiovascular diseases [1,2,3]. EAT is the visceral
fat depot located on the surface of the heart [4] especially around
the epicardial coronary vessels with extension into the myocardi-
um [5,6,7]. As shown by clinical imaging and histological studies,
EAT increases with obesity [5,8] and correlates with intra-
abdominal fat mass [9]. Adipose tissue is now considered as a
metabolically active organ which produces hormones and pro-
inflammatory factors, contributing to the adverse cardiovascular
consequences of obesity [1,5].
The function of EAT is not completely understood [7], possible
roles have been suggested such as lipid storage and endocrine
organ [4,5]. It is also an active inflammatory tissue known to secret
cytokines and chemokines [10,11], which are key factors involved
in atherosclerosis [12]. EAT correlates with the presence of CAD
[5] and is likely to be implicated in its pathogenesis. Previous
studies in humans and rabbits demonstrated that segments of an
artery surrounded by EAT develop atherosclerosis at a faster rate
compared to the intra-myocardial segments of the same artery
[1,13]. Therefore, EAT may play a role especially in the severity of
the pathology [14]. EAT has the potential to be both beneficial
and damaging for the heart function. It is known to collect the
excess of circulating fatty acids, which induce cardiotoxicity [5],
and interfere with the generation and propagation of the
contractile cycle of the heart, causing ventricular arrhythmias
and alterations in repolarization [14]. In addition, due to its high
rate of lipolysis, EAT may serve as a source of free fatty acids
(FFA) to supply myocardial energy demand in times of need,
especially under ischemic conditions [5,14]. In contrast, EAT
thickness was significantly correlated with the severity of CAD [7]
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atherosclerosis [15]. Iacobellis et al. [9] have recently proposed
that echocardiographic EAT thickness measurement might be
useful for cardiometabolic risk stratification.
A number of properties differentiate EAT from other fat depots,
specifically its smaller adipocyte size, low mRNA expression for
several key enzymes involved in lipogenesis (lipoprotein lipase,
stearoyl-CoA desaturase and acetyl-CoA carboxylase-a) [5,14],
slow regression during weight loss [16], and different fatty acid
composition [17], among others [5]. These differences suggest that
EAT presents specific gene regulation patterns. Only two studies
have compared genome-wide transcriptional profiles of EAT with
SAT from the same individuals [10,18]. Moreover, no studies have
compared the genome-wide mRNA profile of EAT with MAT and
SAT from the same individuals.
In the present study, we compared the transcriptional profile of
EAT with that of MAT and SAT from the same individuals by
using whole-genome gene expression microarrays. We found that
EAT and MAT share highly similar mRNA profiles. However,
few genes involved in cardiovascular diseases were up-regulated in
EAT compared to MAT. The expression of the genes ADORA1,
involved in myocardial ischemia and dilated cardiomyopathy [19],
and PTGDS, recently associated with the progression of
atherosclerosis [20,21] were significantly up-regulated in EAT.
Results
Table 1 shows the clinical characteristics of the subjects. BMI
ranged between 24.6 and 30.5 kg/m
2 for subjects used in the
microarray experiment (n=6) and between 22.8 and 35.6 kg/m
2
for subjects used in the qPCR experiment (n=25). No significant
differences were observed in clinical characteristics between
patients used in the microarray and qPCR experiments.
Microarrays
The intrapair correlation coefficients for each tissue were
obtained from normalized expression data and ranged from 0.96
and 0.99 for EAT and SAT; and from 0.94 and 0.98 for MAT
(Figure S1).
Table 2 shows the number of genes that were differentially up-
and down-regulated in each pairwise comparison. A total of 28
probes were significantly differentially up- or down-regulated
between EAT and MAT, 199 between EAT and SAT, and 237
between MAT and SAT. The Tables S1, S2, and S3 list all the
differentially up- and down-regulated probes for the comparisons
EAT vs MAT, EAT vs SAT, and MAT vs SAT, respectively.
These probes correspond to 306 unique genes among the three
pairwise comparisons. Briefly, 23 and 73 genes were differentially
up-regulated in EAT compared with MAT and SAT, respectively.
94 genes were differentially down-regulated in EAT compared to
SAT, whereas no gene was down-regulated in EAT compared to
MAT. Compared to SAT, 116 genes were differentially up-
regulated and 74 genes differentially down-regulated in MAT.
ADORA1 was the most significant differentially up-regulated
gene in EAT compared to MAT. The corresponding probe
(ILMN_1747227) interrogated the 39UTR region of the
ADORA1 transcript (NM_000674.1) and provided a fold change
of 2.9 and a FDR of 0%. However two other probes testing a
different transcript (NM_000674.2) of the same gene were not
significant. PTGDS was the only gene significantly different in the
three comparisons with the highest expression in EAT followed by
MAT and SAT. The overlap of genes differentially expressed
between the 3 comparisons is shown in a Venn diagram (Figure
S2).
Figure 1 shows a heat map of the top 10 genes differentially up-
and down-regulated for the three pairwise comparisons. Full
annotations and main biological processes related with these genes
can be found in Tables S4, S5, and S6. Briefly, 5 and 9 genes in
the top ten genes were involved in inflammatory and immune
response when comparing EAT and MAT with SAT, respectively.
Furthermore, among the 116 genes differentially up-regulated in
MAT vs SAT, 38 genes (33%) are involved in inflammatory
response, such as chemokines and immunoglobulines. Compared
to SAT, 23% (17 of 73) of the differentially up-regulated genes in
EAT are involved in inflammatory response.
Figure S3 shows a heat map of the expression levels of genes
that are specific for various lineages of white blood cells in the
three adipose tissue compartments. Genes specific for B cells
(CD79A and CD79B) were differentially up-regulated in MAT vs
SAT. CD247 that is specific for T cells was also differentially up-
regulated in MAT vs SAT. However the other two genes specific
for T cells (CD3EAP and CD3G) were not different in this
comparison. Specific genes for myeloid cells, monocytes and
megakaryocytes were not different in any of the three compari-
sons.
Mapping of genes to biological pathways
Transcripts deemed significant were analyzed using IPA,
PANTHER, and ToppGene in order to identify molecular
pathways and functional assignments that differ between adipose
tissue compartments. In the comparison EAT vs MAT, three
groups of Toxicity functions were significant, namely cardiotoxicity,
Table 1. Clinical characteristics of the study participants.
Microarrays
subjects
n=6
qPCR subjects
n=25 pvalue
Age (years) 65.5612.6 60.269.0 0.307
BMI (kg/m
2)2 6 . 2 62.2 27.963.4 0.255
Waist circumference (cm) 104.1610.2 101.469.2 0.593
Hypertension 83.3% (5) 56% (14) 0.363
Dyslipidemias 100% (6) 100% (25) 1.000
Type 2 Diabetes 16.6% (1) 32% (8) 0.642
ACEI or ARA 83.3% (5) 64% (16) 0.634
HMG-CoA reductase inhibitors 100% (6) 92% (23) 1.000
ACEI: angiotensin-converting enzyme inhibitors; ARA: angiotensin receptor
antagonist; BMI: body mass index; HMG-CoA reductase inhibitors: hydroxy-
methylglutaryl-coenzyme A reductase inhibitors.
Continuous variables are expressed as mean 6 SD and tested using t-tests.
Dichotomous variables are expressed as percentage (n) and tested using
Fisher’s exact tests.
doi:10.1371/journal.pone.0019908.t001
Table 2. Number of genes up- and down-regulated in each
pairwise comparison.
EAT vs MAT EAT vs SAT MAT vs SAT
Probes Genes Probes Genes Probes Genes
Up 28 23 85 73 143 116
Down 0 0 114 94 94 74
Total 28 23 199 167 237 190
doi:10.1371/journal.pone.0019908.t002
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regulated were involved in cardiotoxicity: acyl-CoA synthetase
long-chain family member 1 (ACSL1), adenosine A1 receptor
(ADORA1), collagen type VI alpha 6 (COL6A6), cysteine-rich
secretory protein LCCL domain containing 2 (CRISPLD2), and
SRY (sex determining region Y)-box 9 (SOX9). Furthermore,
ACSL1 was also involved in hepatotoxicity and PTGDS in
nephrotocixity.
The 22 significant genes in the comparison EAT and MAT
were analyzed using the Function and disease tool in IPA. As a result,
8 genes significantly up-regulated in EAT vs MAT were related to
cardiovascular functions (Figure 2). Interestingly ADORA1 was
the most significant gene differentially expressed between EAT
and MAT, but also the gene more highly linked to cardiovascular
diseases in IPA. The same analysis was performed for the
significantly up-regulated genes in the comparison EAT vs SAT.
In addition to ADORA1 and PTGDS, 11 genes were related to
CAD functions. Similarly, 11 significant down-regulated genes
were related with cardiovascular functions in the same comparison
(Figure 3).
In PANTHER, the only significant Biological process in the
comparison EAT vs MAT was Heart development. Using
ToppGene the single molecular function that was significant in
this same comparison was Neuropeptide receptor binding. In the
comparison EAT vs SAT several molecular functions and
biological processes were called significant including the chemo-
kine activity function, cardiovascular system development and
inflammatory response processes. For the comparison MAT vs
SAT most of the significant molecular functions, pathways and
biological processes are related with immune and inflammatory
response.
qPCR
Validation by qPCR was performed in 25 independent subjects.
Four genes were selected for this validation including ADORA1,
the most significantly gene in the comparison EAT vs MAT (q-
value 0.0); ADRA2A, differentially down-regulated in EAT vs
SAT; LIPE, differentially down-regulated in MAT vs SAT; and
PTGDS, the only gene differentially up-regulated in both EAT
and MAT compared to SAT which is also associated with several
cardiovascular functions. The differential regulations observed in
the microarray experiment were confirmed for ADORA1 (EAT vs
MAT), ADRA2A, LIPE and PTGDS (Figure 4). Although the
comparison of ADORA1 between EAT and SAT was not
significant by qPCR, the fold changes obtained by microarrays
and qPCR followed the same trend (up-regulated, Figure 4 middle
panel).
Using the 6 microarray subjects (Figure 4, green bars), only the
gene LIPE was significantly differentially regulated comparing
MAT with SAT. However, except for ADRA2A in the
comparison MAT vs SAT, all the genes followed the same
direction (up- or down-regulated). It should be noted that
ADRA2A was not significant for this comparison in the
microarray experiment.
There was no significant difference in the expression of the 4
genes tested by qPCR between patients with and without type 2
diabetes. Furthermore, no significant correlation was observed
between the expression of these four genes and BMI.
Discussion
Cardiovascular disease (CVD) is a leading global cause of death.
Previous studies found a significant relation between EAT volume
and the presence of CAD [22], but the role of EAT in CAD and
other CVDs is still unclear. To expand our knowledge about the
function of EAT and its relation with CVDs, we performed a
microarray experiment to compare the gene expression profile of
EAT, MAT, and SAT from subjects with CAD.
A total of 306 genes were significantly differentially regulated
among three adipose tissues comparisons. Several genes involved
in inflammatory and immune responses were identified among the
top differentially up-regulated genes comparing EAT and MAT
with SAT. Likewise, Mazurek et al. [10] found that EAT exhibited
significantly higher expression levels of chemokines, inflammatory
cytokines, and immune response genes compared to SAT,
independently of obesity and diabetes. In addition, other studies
[10,23] showed that when compared to SAT the omental fat,
incidentally a visceral fat with similar embryologic origin to EAT,
express higher level of IL-6 and other cytokines. Another study
[24] has correlated the thickness of EAT with the plasma levels of
Figure 1. Heat map of the top 10 genes differentially up- and down-regulated for the three pairwise comparisons. The samples and
genes are illustrated in columns and rows, respectively. Red and green represent high and low expression, respectively. The full names and biological
processes related with these genes are provided in Tables S4, S5, and S6.
doi:10.1371/journal.pone.0019908.g001
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receptor/IL-6 in obese subjects. A previous microarray experi-
ment identified the pro-inflammatory enzyme phospholipase A2
group IIA (PLA2G2A) as the top gene encoding for a secreted
protein that was differentially up-regulated in EAT compared to
SAT in both patients with or without CAD [18]. The single probe
that interrogated this gene in our study was also differentially up-
regulated in EAT compared to SAT (fold change=1.20), but was
Figure 2. Cardiovascular functions linked to up-regulated genes in EAT compared to MAT. ACSL1, Acyl-CoA synthetase long-chain family
member 1; ADORA1, adenosine A1 receptor; HSD17B1, hydroxysteroid (17-beta) dehydrogenase 1; MGP, matrix Gla protein; NMB, neuromedin B;
PTGDS, prostaglandin D2 synthase; SERPINA5, serpin peptidase inhibitor -clade A (alpha-1 antiproteinase, antitrypsin)- member 5; and SOX9, SRY (sex
determining region Y)-box 9. *Interaction with itself. RActs on.
doi:10.1371/journal.pone.0019908.g002
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adiponectin (ADIPOQ) was lowered in EAT compared to SAT
[25]. Again our results were in the same direction (fold
change=0.84 comparing EAT vs SAT), but not significant. A
larger sample size may be required to confirm the differential
expression of PLA2G2A and ADIPOQ between EAT and SAT.
We observed highly similar mRNA expression patterns between
EAT and MAT. Only 23 genes were differentially expressed
between these tissues. Mahabadi et al. [26] showed that the amount
of pericardial and intra-abdominal fat, but not MAT, were
significantly associated with CVD. Hence, the location of EAT
over the myocardium and its direct contact with the coronary
arteries is supporting the idea that local and paracrine effects of
secreted molecules by EAT have the potential to influence the
development of CAD and/or myocardial dysfunction.
We validated four genes by qPCR. These genes were selected
because they were among the top differentially regulated genes,
but also based on their importance in CAD and the biology of the
adipose tissue. ADORA1 was the most significant differentially up-
regulated gene in the microarrays experiment comparing EAT
with MAT. It is a G protein coupled-receptor (GPCR), which
couples to Gi to decrease the secondary messenger cAMP.
ADORA1 agonists have potential therapeutic uses to treat CVD
[27]. The activation of ADORA1 has an important role in
protecting the myocardium from ischemic damage. Under
ischemic conditions, the concentration of extracellular endogenous
adenosine increases as a protective mediator. Up-regulation of
ADORA1 in the heart of transgenic mice provides additional
cardioprotection to that offered by adenosine [28,29]. In these
mice there was a decrease in cell necrosis, improvement of
Figure 3. Cardiovascular functions linked to up- (red) and down-regulated (green) genes in EAT compared to SAT. ACTG2, actin,
gamma 2, smooth muscle, enteric; ADRA2A, adrenergic, alpha-2A-, receptor; AMPH amphiphysin; BCHE, butyrylcholinesterase; C6, complement
component 6; CBS, cystathionine-beta-synthase; CNTNAP2, contactin associated protein-like 2; COL3A1, collagen, type III, alpha 1; COL12A1, collagen,
type XII, alpha 1; CTSG, cathepsin G; CXCR4, chemokine (C-X-C motif) receptor 4; FRAS1, Fraser syndrome 1; MAOB, monoamine oxidase B; MARCKSL1,
MARCKS-like 1; MYH11, myosin, heavy chain 11, smooth muscle; NOX4, NADPH oxidase 4; NTRK2, neurotrophic tyrosine kinase, receptor, type 2;
PAMR1, peptidase domain containing associated with muscle regeneration 1; PDE1A, phosphodiesterase 1A calmodulin-dependent; RARB, retinoic
acid receptor beta; SEMA3C, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C; and SERPINE2, serpin
peptidase inhibitor clade E (nexin, plasminogen activator inhibitor type 1), member 2. *Interaction with itself.
doi:10.1371/journal.pone.0019908.g003
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nous ADORA1 and ADORA3 agonists reduced cardiac infarct
size and improved functional recovery in isolated heart models
[30]. Myocardial injuries after ischemia-reperfusion induce
apoptosis, and ADORA1 overexpression attenuated this apoptotic
response [28]. Taken together, these studies confirm the
importance of ADORA1 in the pathobiology of heart diseases,
but do not explain how the differential up-regulation of this
receptor in adjacent adipose tissues may affect myocardial or
vascular function. In this regard, binding of adenosine to
ADORA1 is well recognized to inhibit lipolysis, and omental fat
cells are less responsive to this nucleoside than subcutaneous ones
[31] because of a lower ADORA1 density in the former adipocytes
[32]. Accordingly it is tempting to speculate that differentially up-
regulation of ADORA1 is a negative feedback mechanism to
attenuate the higher FFA release observed in EAT [5].
Figure 4. Comparison of fold changes for ADORA1, ADRA2A, LIPE, and PTGDS. EAT vs MAT (A), EAT vs SAT (B) and MAT vs SAT (C). The red
bars represent the fold changes obtained by microarrays. The green and violet bars represent the fold changes obtained by qPCR for the microarrays
and qPCR subjects, respectively. {Significant in the microarray experiment. *p,0.05, **p,0.001, and ***p,0.0001.
doi:10.1371/journal.pone.0019908.g004
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which mediates the effect of the endogenous catecholamines. It
plays a central role in the regulation of systemic sympathetic
activity and hence cardiovascular responses such as heart rate and
blood pressure [33]. ADRA2A is important in the regulation of
both cardiovascular and endocrine systems [34]. Targeted
disruption of this gene causes hypertension, tachycardia and
impaired baroreceptor reflexes in mice [35,36]; and its overex-
pression in pancreatic islets contributes to type 2 diabetes [37].
The DraI allele was previously associated with increased
sympathetic activity, thereby predisposing to hypertension [35].
In our study, ADRA2A was significantly differentially down-
regulated in EAT and MAT compared to SAT. Similarly, Vohl et
al. [23] observed that ADRA2A is differentially down-regulated in
omental compared to SAT. Thus, the lower expression of
ADRA2A in EAT and omental adipose tissues may suggest a
lower sensitivity to antilipolytic signals as already confirmed by
Maurie `ge et al. [38,39] and Vikman et al. [40]. It is known that
the rate of lipolysis in EAT is increased compared to other fat
depots such as popliteal or perirenal [5], which might be in part
mediated by a low expression of ADRA2A.
LIPE is an enzyme with lipolytic properties and catalyzes the
rate-limiting step of lipolysis by hydrolyzing the stored triacylgly-
cerols and diacylglycerols into fatty acids and glycerol [41]. In our
study, LIPE was significantly differentially down-regulated in EAT
and MAT compared to SAT. This finding is concordant with the
higher maximum lipolytic capacity, LIPE activity and mRNA
expression in subcutaneous abdominal compared to omental fat
cells [42]. Yet, visceral fat cells are known to have higher lipolytic
activity compared to subcutaneous adipocytes. This situation may
be partly explained by increased insulin action and alpha 2-
adrenergic receptor mediated antilipolysis observed in subcutane-
ous fat depots [38,40,43]. In contrast, Fain et al. [44] found that
EAT expressed higher levels of LIPE compared to SAT in a mixed
population of men and women. However, our findings also
support those of Vohl et al. [23] who found that LIPE was
differentially down-regulated in visceral fat compared to SAT in
men. Other studies have found no difference in the expression of
LIPE between visceral and subcutaneous fat [45,46]. Differences
in adipose tissue gene expression between men and women may
account for such disparities [47,48]. Cellular heterogeneity may
also be considered as Montague et al. [45] studied isolated
adipocytes (being separated from the stromal-vascular cells of the
adipose tissue), while the whole adipose tissue was homogenized
before RNA extraction in our study and the one of Vohl et al.
[23]. Since LIPE is well known to be differentially up-regulated in
adipocytes compared to preadipocytes [49], and as it is also
expressed in macrophages [50], cell heterogeneity in whole
adipose tissue biopsies might explain the differences between
studies.
PTGDS is an enzyme involved in the synthesis of prostaglan-
din D2 (PGD2) [51]. PGD2 is a potent anticoagulant and
vasodilatator [20]. PTGDS overexpression is thought to be an
adaptative mechanism to prevent cardiovascular injuries because
of its anti-inflammatory properties [51]. The PTGDS biopro-
ducts PGD2 and 15d-PGJ2 lead to a reversion of the
inflammatory state and plaque stabilization in human athero-
sclerosis [52]. PTGDS knockout mice developed atherosclerosis
when compared with controls [53]. Its expression may be
increased to protect against platelet aggregation in atherosclerotic
blood vessels [54] and to inhibit the growth phenotype of vascular
smooth muscle cells [54]. Moreover, PTGDS is considered a
suitable biomarker of CAD as its levels in serum increase in
subjects with stable CAD and with the severity of the disease [20].
In the present study, PTGDS was significantly differentially up-
regulated in EAT compared to MAT and SAT. This finding
corroborates the study by Fain et al. [44], which showed higher
levels of this transcript in EAT compared to substernal and
subcutaneous fat in a group of men and women undergoing
CABG [44]. The fact that the coronary arteries and their main
epicardial branches are embedded in EAT [5] suggests that part
of the higher PTGDS levels observed in atherosclerotic plaques of
coronary arteries, compared to the internal mammary or the
carotid arteries [20], may come from EAT. In our study, two
other genes involved in the arachidonic acid metabolism were
also differentially up-regulated in EAT, including ACSL1, the
first enzyme in the incorporation of arachidonic acid into
phospholipids, and NMB, that stimulates arachidonic acid
release. This suggests the utilization of arachidonic acid and the
production of pro-inflammatory mediators by EAT. Whether this
differentially up-regulation of genes involved in the arachidonic
metabolism is a cause or a consequence of CAD remains to be
elucidated.
This study has some limitations. First, it was limited to subjects
with CAD, thus results cannot be extrapolated to non-CAD
subjects. Measuring the levels of ADORA1, ADRA2A and
PTGDS in CAD and non-CAD subjects would be of great
interest to confirm their possible role in the particular character-
istics of EAT and to improve our knowledge about the functions of
this adipose tissue. Second, as we measured mRNA expression
only, quantification of protein levels may reinforce or weaken the
results observed, since protein levels can vary according to post-
transcriptional and post-translational processes. Third, the sample
size used in the microarray experiment is small. Four genes were
robustly confirmed by qPCR in a larger sample size and similar
experiments will be required to confirm all other genes claimed
significant in the microarray data set. Finally, we did not take into
account the various cell types which composed the different fat
depots. Adipose tissue contains adipocytes, preadipocytes, fibro-
blasts, vascular cells, and macrophages. This heterogeneity may
modify gene expression levels depending on the proportion of each
cell type. In fact, our gene expression data seems to confirm
previous observations showing a greater proportion of B and T
cells in EAT and MAT compared to SAT (Figure S3) [10,55].
Accordingly, genes differentially expressed in this study may reflect
the different proportion of cell types in adipose tissue depots.
Nonetheless, this study identified several genes with potential
implications in the pathogenesis of heart disorders that are
differentially regulated in EAT.
In conclusion, the gene expression profiles of EAT and MAT
are more alike compared to SAT. An important proportion of
genes involved in inflammation are differentially up-regulated in
EAT and MAT compared to SAT, confirming that visceral
adipose tissue may participate to heart diseases, including CAD.
Our study also confirms the differentially up-regulation of PTGDS
in EAT compared to MAT and SAT. To the best of our
knowledge, it is the first time that the higher expression of
ADORA1 and the lower expression of ADRA2A in EAT
compared to SAT is documented, suggesting that the balance
between these two genes may account for some of the regional
differences observed in lipolysis. The differential up-regulation of
PTGDS and ADORA1 suggests a possible cardioprotective role of
EAT toward CAD, hypertension, and other cardiovascular
dysfunctions. Moreover, the higher expression of genes involved
in the arachidonic acid pathway in EAT may influence the pro/
anti-inflammatory properties of this tissue and will require
additional investigations. Overall, our results provide insights
about the biology of EAT and its potential implication in CAD.
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Ethics Statement
A written informed consent was obtained from all participants.
The study was approved by the ethics committee of the Institut
universitaire de cardiologie et de pneumologie de Que ´bec.
Study population
A total of 31 predominantly overweight men who underwent
coronary artery bypass grafting (CABG) at the Institut universi-
taire de cardiologie et de pneumologie de Que ´bec participated in
the study. The subjects presented 1 to 3 affected vessels. The
clinical characteristics of the subjects involved in the microarray
and qPCR validation experiments are summarized in Table 1.
The inclusion and exclusion criteria were the same for both
groups. Subjects were consecutively selected first for the micro-
array experiment and then the qPCR experiment based on tissues
availability. To reduce heterogeneity, only adipose tissues from
white male subjects were selected. The average age of subjects in
the microarray experiment was 66 years (range 48 to 76 years). All
subjects had a body mass index (BMI),40 kg/m
2, were non-
smokers or had stopped smoking for at least 6 months. The
exclusion criteria were impaired renal function, chronic inflam-
matory or auto-immune diseases, aortic or mitral valve replace-
ment, cancer, insulin treatment, and/or chronic obstructive
pulmonary disease.
BMI was calculated as weight in kilograms divided by height in
meters squared [56]. Obesity, overweight, and normal weight were
defined as BMI$30 kg/m
2, 25 to 29.9 kg/m
2, and 20 to 24.9 kg/
m
2, respectively. Waist circumference was obtained using a
measuring tape directly on the skin with the subject standing.
Measurements were taken at the end of expiration at the level
midway between the lower rib margin and the iliac crest. The
diagnosis of hypertension was based on a resting systolic or
diastolic blood pressure .140 or .90 mmHg, respectively, or an
actual hypertensive treatment. Dyslipidemia was defined as low-
density lipoprotein cholesterol $3 mmol/L or the utilization of
hypolipidemic agents. Nine out of 31 subjects had a clinical
diagnosis of type 2 diabetes. Clinical characteristics of patients
between the microarrays and the qPCR groups were tested using
t-tests or Fisher’s exact tests as appropriate. Pearson correlation
tests were used to assess the relationship between gene expression
and BMI.
Adipose tissue collection
Adipose tissues from 3 compartments, namely epicardial,
mediastinal, and subcutaneous, were taken from the chest of each
individual. EAT correspond to the adipose depot in direct contact
with the heart located between the myocardium and the visceral
pericardium. MAT was defined as the fat within the mediastinum,
outside the pericardial sac. The samples were collected from
surgeries performed between October 2007 and August 2009.
Immediately after resection, the tissues were snap-frozen in liquid
nitrogen and stored in a local biobank at 280uC until RNA
isolation.
RNA extraction
RNA was isolated from 100 mg of tissue using the RNeasy
Lipid Tissue Mini Kit (QIAGEN, Mississauga, Ontario) according
to manufacturer’s instructions. Before proceeding with micro-
arrays experiments, the integrity of the RNA was assessed using
the Agilent 2100 Bioanalyzer (Agilent technologies, Santa Clara,
California) (Table S7). RNA concentration and purity for the
quantitative real-time PCR (qPCR) validation was measured by
the GeneQuant pro UV/Vis Spectrophotometer (Biochrom,
Cambridge, UK).
Microarrays
Adipose tissues of 6 subjects were chosen for whole-genome gene
expression analysis. For each subject, gene expression was evaluated
in the 3 adipose tissue compartments using the HumanWG-6 v3.0
expression BeadChips (Illumina, San Diego, California). The latter
interrogatedmore than 48,000probesderived from humangenes in
the NCBI RefSeq and UniGene databases. The RNA was labeled
and hybridized using a standard Illumina protocol performed at the
McGillUniversityand Ge ´nomeQue ´becInnovationCentre(http://
www.gqinnovationcenter.com). Briefly, RNA extracted from the
adiposetissuewasconvertedtosingle-stranded cDNAusinganoligo
(dT) tagged with a phage T7 enabling theamplification and labeling
of the cDNA by an in vitro transcription reaction which
incorporates biotin UTP. The labeled cRNA was then hybridized
to the chip at 58uC overnight, and washed the following day. Signal
was developed using streptavidin-Cy3 and the chip was scanned by
the Illumina BeadArray Reader. The GenomeStudio
TM software
was used to generate raw data resulting in standard file formats
containing the signal values per probe. The complete data set has
been deposited in the National Center for Biotechnology Informa-
tion’s Gene Expression Omnibus repository [57] and are accessible
through GEO Series accession number GSE24425 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE24425).
Microarray analysis
The raw data was log2-transformed and quantile normalized
using the lumi package in R [58,59]. All probes were considered in
the analyses and no filter was applied to eliminate genes with low
expression signals in one or many samples. The Significance
Analysis of Microarrays (SAM) method [60] was utilized to
identify probes differentially expressed among three pairwise
comparisons (EAT vs MAT, EAT vs SAT, and MAT vs SAT).
The false discovery rate (FDR) and the fold change threshold were
set at 5% and 2.0, respectively. A false discovery rate of 10% was
also explored for the comparison between EAT vs MAT. The fold
change was obtained by raising 2 to the power of the mean
difference in expression between any two adipose tissue compart-
ments. Each probe was treated independently and transcripts
interrogated by multiple probes were not summarized.
qPCR
qPCR was used to validate the expression of four significant
genes in EAT, SAT and MAT of 25 subjects (hence referred to as
qPCR subjects) as well as the 6 microarrays subjects. The
QuantiTect Reverse Transcription Kit (QIAGEN) was used to
synthesize cDNA from 2 mg of RNA of each sample as described
by the manufacturer. GAPDH was utilized as a reference gene as
previously used in gene expression studies conducted in adipose
tissues [10,47,61,62,63]. The latter gene was interrogated by three
probes in the microarray experiment and similar signal intensities
were observed in the three adipose tissues. The primers were
designed using the software Primer3 v.0.4.0 (http://frodo.wi.mit.
edu/primer3) and synthesized by Integrated DNA Technologies
(Toronto, Ontario). PCR primers were tested In Silico using
BLAT in UCSC to confirm their binding to a unique region of the
genome and the absence of polymorphism. The genes, forward (F)
and reverse (R) primer sequences used for qPCR were GAPDH (F:
59- ATGTTCGTCATGGGTGTGAA and R: 59-GGTGC-
TAAGCAGTTGGTGGT), ADORA1 (F: 59-GCGAGTTCGA-
GAAGGTCATC and R: 59-GCTGCTTGCGGATTAGGTAG),
ADRA2A (F: 59-CGACCAGAAGTGGTACGTCA and R: 59-
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GTGGGCGCAAGTC and R: 59-AAGTCCCTCAGGGTCA-
GGTT), and PTGDS (F: 59-AACCAGTGTGAGACCCGAAC
and R: 59-AGCGCGTACTGGTCGTAGTC). The lengths of the
amplicons were between 88 and 131 bp. The same cDNA sample
was used to prepare the standard curves for each gene and was
made from a pool of 36 SAT samples. For each gene, the
experimental samples were tested in triplicate using the Rotor-
Gene 6000 (Corbett Life Science, Concorde, Australia) in a final
reaction volume of 20 ml containing 5 mlo f5 0 6 diluted cDNA,
10 mlo f2 6QuantiTect SYBR Green PCR Kit (QIAGEN), and
primers (0.3 mM for ADORA1, GAPDH, LIPE, and PTGDS; and
0.5 mM for ADRA2A). The final concentration of MgCl2 was
3 mM for ADORA1 and 2.5 mM for the other genes. The qPCR
conditions were the same for all genes, 95uC for 15 min, and then
50 cycles at 94uC for 10 sec, 59uC for 30 sec, and 72uC for 30 sec.
A melting curve analysis was performed at the end of each run and
all showed a single peak, indicating specificity of the amplified
products. According to the Rotor-gene 6000 series software v1.7
(Corbett Life Science), all standard curves had a correlation
coefficient and efficiency higher than 0.98 and 0.9, respectively.
For each gene, the nanograms of cDNA of each sample were
calculated according to the standard curve method and normal-
ized to GAPDH. The fold changes were obtained by dividing
nanograms of cDNA between two groups of tissues (e.g. EAT vs
SAT). Paired t-tests were used to assess significance differences in
gene expression between any pairwise comparisons.
Mapping of genes to biological pathways
TheIngenuityPathwayAnalysissystem(IPA)(IngenuitySystems,
www.ingenuity.com) was used to identify the principal biofunctions
and diseases among the differentially expressed genes. Three input
files were uploaded in IPA, one by pairwise comparison. The input
files included the 48804 probes present in the microarrays, with
their respective fold changes and the significant q-values obtained
from SAM. Core analyses were then performed to overlay the
results of each comparison into the Ingenuity Knowledge Base in
order to identify particular diseases, molecular or cellular functions,
metabolic and cell signaling pathways that were particularly
enriched for genes claimed significant in our microarray experi-
ment. In addition to IPA, the lists of significant genes were
interpreted using the PANTHER classification system [64,65] and
the ToppFun tool in the ToppGene Suite [66].
Supporting Information
Figure S1 A) EAT, B) MAT, and C) SAT intrapair correlation
coefficients obtained from normalized expression data.
(PNG)
Figure S2 Venn diagrams showing the number of genes
differentially expressed in the three pairwise comparisons. A)
and B) shows the number of differentially up- and down-regulated
genes, respectively. There was no significant gene down-regulated
in EAT compared to MAT.
(JPG)
Figure S3 Heat map showing the expression of inflammatory
and immune cell markers in the microarray experiment. A) EAT
vs MAT, B) EAT vs SAT, and C) MAT vs SAT. The samples and
genes are illustrated in columns and rows, respectively. Red and
green represent high and low expression, respectively. Gene
symbols are provided on the right side of each panel with cell type
specificity in parentheses. The fold changes are indicated in
parentheses. The asterisks represent probes that are claim
significant based on the microarray experiment.
(TIF)
Table S1 SAM output listing all the significant up- and down-
regulated probes in the comparisons EAT vs MAT.
(XLS)
Table S2 SAM output listing all the significant up- and down-
regulated probes in the comparisons EAT vs SAT.
(XLS)
Table S3 SAM output listing all the significant up- and down-
regulated probes in the comparisons MAT vs SAT.
(XLS)
Table S4 Top 10 genes significantly up- and down-regulated in
EAT vs MAT.
(DOC)
Table S5 Top 10 genes significantly up- and down-regulated in
EAT vs SAT.
(DOC)
Table S6 Top 10 genes significantly up- and down-regulated in
MAT vs SAT.
(DOC)
Table S7 RNA extraction yields and RNA integrity of the
microarrays samples measured with the 2100 Bioanalyzer
(Agilent).
(DOC)
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